AI Article Synopsis
- Cannabinoids have a long history of use for pain relief, and recent research focuses on their effectiveness in treating chronic pain conditions.
- An open-label study with 13 patients suffering from chronic nonmalignant pain tested the impact of oral Delta-9-tetrahydrocannabinol (Delta-9-THC), revealing that 5 patients had a positive response, while 8 did not.
- Most patients tolerated the treatment well, though some experienced adverse events, suggesting that while oral THC could benefit certain patients, more research is needed to identify those who would most likely respond to it.
Article Abstract
Cannabinoids have been used for pain relief for centuries and recent studies have investigated their analgesic and anti-inflammatory mechanisms, as well as clinical efficacy, in treating chronic pain. We report an open-label study addressed to evaluate the effect and adverse events of orally administered Delta-9-tetrahydrocannabinol (Delta-9-THC) in 13 patients with chronic nonmalignant pain (CNMP) unresponsive to conventional pharmacotherapy. The effect of the treatment was assessed on an eight-item HRQoL questionnaire. Five out of 13 patients reported adequate response to the treatment while eight patients reported inadequate or no response. Seven patients did not experience any adverse events (AEs), six patients reported AEs, two of which discontinued the treatment. We conclude that oral THC may be a valuable therapeutic option for selected patients with CNMP that are unresponsive to previous treatments, though further research is warranted to characterize those patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/15360280802251215 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!